THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets
暂无分享,去创建一个
Arthur Christopoulos | Christopher Southan | Jörg Striessnig | John A Peters | Elena Faccenda | Simon D Harding | Adam J Pawson | Joanna L Sharman | Jamie A Davies | Doriano Fabbro | Stephen P. H. Alexander | Michael Spedding | Jane F Armstrong | Stephen Ph Alexander | Eamonn Kelly | Alistair Mathie | Emma L Veale | John A Cidlowski | O Peter Buneman | Anthony P Davenport | C. Southan | O. Buneman | D. Fabbro | A. Christopoulos | M. Spedding | A. Mathie | J. Cidlowski | J. Davies | J. Armstrong | E. Faccenda | S. Harding | J. Sharman | A. Davenport | J. A. Peters | E. Kelly | J. Striessnig | E. Veale
[1] Carsten Janke,et al. The tubulin code at a glance , 2017, Journal of Cell Science.
[2] Richard R. Neubig,et al. Regulators of G-Protein signalling as new central nervous system drug targets , 2002, Nature Reviews Drug Discovery.
[3] Shelley B Hooks,et al. Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins. , 2018, Cellular signalling.
[4] Souvik Banerjee,et al. Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy , 2019, Medicinal research reviews.
[5] D. Zamanillo,et al. Sigma-1 receptor and inflammatory pain , 2015, Inflammation Research.
[6] Douglas M. Yau,et al. Non-canonical functions of RGS proteins. , 2010, Cellular signalling.
[7] Habibeh Khoshbouei,et al. The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction. , 2018, Pharmacology & therapeutics.
[8] Shang-Yi Tsai,et al. The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. , 2016, Trends in pharmacological sciences.
[9] Maija Dambrova,et al. Allosteric Modulators of Sigma-1 Receptor: A Review , 2019, Front. Pharmacol..
[10] Anil K Sood,et al. Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer , 2014, Clinical Cancer Research.
[11] B. Sjögren,et al. The evolution of regulators of G protein signalling proteins as drug targets – 20 years in the making: IUPHAR Review 21 , 2017, British journal of pharmacology.
[12] Michael Kahn,et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update , 2015, Nature Reviews Clinical Oncology.
[13] Richard R Neubig,et al. Thinking Outside of the “RGS Box”: New Approaches to Therapeutic Targeting of Regulators of G Protein Signaling , 2010, Molecular Pharmacology.
[14] C. Rousseaux,et al. Sigma receptors [σRs]: biology in normal and diseased states , 2015, Journal of receptor and signal transduction research.
[15] Mark P. Mattson,et al. Notch signaling and neuronal death in stroke , 2018, Progress in Neurobiology.
[16] Carsten Janke,et al. Tubulin Posttranslational Modifications and Emerging Links to Human Disease , 2018, Cell.
[17] Franz Oswald,et al. The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFβ/BMP and hypoxia pathways. , 2016, Biochimica et biophysica acta.
[18] Wu-Min Deng,et al. Ligand-Independent Mechanisms of Notch Activity. , 2015, Trends in cell biology.
[19] Diego Bonatto,et al. Anti‐mitotic agents: Are they emerging molecules for cancer treatment?☆ , 2017, Pharmacology & therapeutics.